Loading quotes...

Forecast

The analysts' average price target is €24.78 (-17.59%). The median is €23.23 (-22.75%).

Buy	9
Hold	13
Sell	2

News Go to news feed

Doximity falls after downgrade by Freedom Capital

Doximity shares dropped 5.6% after Freedom Capital cut its rating from "buy" to "hold" while raising the price target from $24 to $27. The company reported Q1 results above expectations and raised its revenue outlook but lowered its EBITDA forecast to fund increased investments in AI development and computing power. Freedom Capital reduced its mid-point EBITDA estimate for 2027 from $329 million to $319 million and cited a balanced risk-reward profile for the downgrade; competition from Epic and OpenEvidence and tight pharma budgets remain risks, while AI search contracts are showing early positive momentum. » More on de.investing.com
Doximity CEO sells 8,505 shares to cover tax withholding after equity vesting

Doximity CEO Jeffrey Tangney sold 8,505 Class A shares on August 15 to satisfy tax withholding from vested awards, a non-discretionary transaction that reduced his direct stake by roughly 0.3% to 2,531,955 shares (about 1% ownership). The sale does not reflect a market judgment by Tangney and three other insiders had similar withholdings the same day. Company results show slowing top-line growth, margin pressure from rising AI compute costs, and a guidance lull as AI-related revenue recognition is expected later in the year, while the stock has fallen over 60% in the past year. » More on finance.yahoo.com
Doximity granted president 150,000 options as he sold small stake to cover taxes

Doximity president Steven L. Zatz sold 4,482 Class A shares in a non‑discretionary sell‑to‑cover to satisfy tax withholding after RSU vesting and retains 51,864 shares (~$1.29m at $24.80). The company granted Zatz 150,000 options on July 22 with a $20.49 strike that begin vesting in July 2027, tying future pay to stock appreciation. Doximity reported Q2 revenue of $156.6m (7% growth) and raised its full‑year range while AI compute costs lowered gross margin to 87.5% and adjusted EBITDA fell 6% to $74.8m; management says higher‑than‑expected AI usage should drive future revenue recognition. Investors should note the option grant links executive upside to stock performance as AI‑related costs and upcoming AI revenue recognition will affect margins and earnings. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, DOXIMITY INC DL-,001 has already paid €0.54 in dividends. The last payout was in July 2022.

Financials

In the last quarter, DOXIMITY INC DL-,001 had revenue of €137.23M and net profit of €21.31M

(EUR)	June 2026	YoY
Revenue	137.23M	10.85%
Gross profit	116.47M	5.50%
Net profit	21.31M	52.90%
EBITDA	39.12M	31.11%

Fundamentals

Metric	Value
Market capitalization	€5.29B
Number of shares	178.25M
52-week high/low	€61.65 - €15.32
Dividends	No
Beta	1.22
P/E ratio	37.35
PEG ratio	-1.30
P/B ratio	6.62
P/S ratio	9.04

Company profile

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.

Name	DOXIMITY INC DL-,001
CEO	Jeffrey A. Tangney
Headquarters	San Francisco, ca USA
Website	doximity.com
Sector	Health Care
Industry	Health Care Technology
IPO	01/02/2008
Employees	880